-
Drug, Healthcare and Patient Safety
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
Review
(1770) Views (678) Full article downloads
Authors: Sarah Horton, Maya H Buch, Paul Emery
Published Date August 2010
Volume 2010:2 Pages 101 - 119
DOI: http://dx.doi.org/10.2147/DHPS.S6317
Sarah Horton1, Maya H Buch2, Paul Emery21Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Abstract: Rheumatoid arthritis (RA) is a systemic inflammatory disease in which chronic inflammation leads to joint destruction and extra-articular complications. Early and effective inhibition of inflammation is critical in order to prevent the progressive joint damage that occurs rapidly after onset of the disease. In the past, treatment for this purpose was limited to conventional disease-modifying antirheumatic drugs (DMARDs), which were often suboptimal. Within the last decade however, the development of biologic therapies, targeted against cytokines and cells involved in the inflammatory process, has revolutionized the management of RA. Disease remission is now an achievable goal in newly diagnosed patients. Since the advent of the first tumor necrosis factor-α inhibitor in 1999, other biologics have proved necessary as individuals respond to varying degrees with different therapies. Several are now available for the treatment of patients with RA that remains active despite DMARD treatment. This article reviews the evidence, over the last decade, of the efficacy and safety of biologic therapies used in this context, and the recent clinical data supporting the use of biologic therapy earlier in the disease process as first-line therapy.
Keywords: rheumatoid arthritis, biologic therapy, tumor necrosis factor, abatacept, rituximab, tocilizumab, safety
Readers of this article also read:
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




